H2L 5765834

Cat. No.:	HY-15706
CAS No.:	420841-84-5
Molecular Formula:	$C_{21}H_{12}N_2O_7$
Molecular Weight:	404.33
Target:	LPL Receptor
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	H2L 5765834 is an antagonist of lysophosphatidic acid receptors LPA_1, LPA_3, and LPA_5, with IC_{50}s of 94, 752, and 463 nM respectively[1].		
IC_{50} & Target	LPA_1 Receptor 94 nM (IC_{50})	LPA_3 Receptor 752 nM (IC_{50})	LPA_5 Receptor 463 nM (IC_{50})
In Vitro	H2L 5765834 displays no effect on LPA_2 or LPA_4 receptors[1]. H2L 5765834 inhibits LPA-induced platelet shape change with an IC_{50} of 13.73±2.52 μM[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
In Vivo	H2L 5765834 (20 mg/kg; i.p.) could not affect the LPA-induced decrease of alanine transaminase (ALT) in the acetaminophen (APAP) overdose-induced acute liver injury model[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

REFERENCES

[1]. Williams JR, et, al. Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. J Biol Chem. 2009 Jun 19; 284(25): 17304-19.

[2]. Bae GH, et, al. Lysophosphatidic acid protects against acetaminophen-induced acute liver injury. Exp Mol Med. 2017 Dec 8; 49(12): e407.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA